相关实验视频
Updated: Sep 16, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.8K
作为smTNF调节器,发现了口服有效的桥梁皮佩拉辛
Zhiguo Bian1, Robert G Schmidt1, Noel S Wilson1
1AbbVie Inc, North Chicago, Illinois 60064, United States.
Journal of medicinal chemistry
|July 9, 2025
概括
研究人员开发了针对炎症性疾病的瘤亡因子α (TNFα) 的新型小分子抑制剂. 这些口服有效的化合物显示出临床开发的潜力,为生物药物提供了替代品.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤亡因子α (TNFα) 是炎症和自身免疫性疾病的关键调解者.
- 针对TNFα的生物药物已经显示出有效性,但在小分子开发方面面临挑战.
- 由于强烈的受体结合和三元体稳定性,难以通过小分子破坏TNFα信号传输.
研究的目的:
- 发现和开发新的TNFα小分子抑制剂.
- 为了克服与小分子向TNFα相关的挑战.
- 为了识别具有潜在的口服和临床开发的化合物.
主要方法:
- 利用分子动力学模拟和脚手架跳跃进行初始命中发现.
- 采用基于结构的设计,以优化潜在客户.
- 在小鼠炎症模型中评估了口服疗效 (葡萄糖-6-酸盐异合酶诱导的脚胀).
主要成果:
- 确定了一种新的小分子TNFα抑制剂,具有桥接-皮佩拉核心.
- 优化的分子表现出与原型相比的强度,物理化学性能得到改善.
- 这种化合物在体内显示出显著的口服疗效,与TNFα抗体相当.
- 估计有效人体剂量为每天一次200毫克.
结论:
- 新型小分子TNFα抑制剂与桥梁-皮佩拉核心已成功开发.
- 这些抑制剂具有有利的物理化学特性,并证明了口服疗效.
- 这些发现支持这些小分子的临床开发潜力,作为TNFα介导疾病的替代治疗策略.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
258
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
258
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
412
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
412
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227

